Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 220

Posts Tagged ‘healthcare’

COVID-19: MEPs free up over €3 billion to support EU healthcare sector

Posted by fidest press agency su domenica, 19 aprile 2020

The EU funds should directly support healthcare systems in EU member states in their fight against the coronavirus pandemic. The initiative should allow the EU to buy urgent medical supplies, such as masks and respiratory equipment, transport medical equipment and patients in cross-border regions, finance the recruitment of additional healthcare professionals to be deployed to hotspots across the European Union, as well as helping member states to construct mobile field hospitals.A total of €3.08 billion from the EU budget will be channelled mainly through the Emergency Support Instrument (€2.7 billion) and through rescEU (€380 million).The package includes additional funds to finance repatriation flights (€45 million) under EU Civil Protection Mechanism to reunite families stranded in third countries, to provide more resources for the European Centre for Disease Prevention and Control (€3.6 million), but also to help Greece deal with increased migratory pressures (€350 million), and to support Albania’s post-earthquake reconstruction (€100 million). Budget Committee MEPs already called in March for available financial means remaining in the 2020 budget to be mobilised.

Posted in Estero/world news, Politica/Politics | Contrassegnato da tag: , , , | Leave a Comment »

Cerba Healthcare acquisisce il Centro Diagnostico Solbiatese

Posted by fidest press agency su martedì, 3 marzo 2020

Cerba Healthcare Italia, azienda del gruppo internazionale Cerba Healthcare, consolida la sua posizione come punto di riferimento nella diagnostica ambulatoriale e nelle analisi di laboratorio con la prima acquisizione del 2020: quella del CDS – Centro Diagnostico Solbiatese di Solbiate Olona (VA), presidio medico-sanitario accreditato al SSR che serve un ampio bacino d’utenza nel Varesotto offrendo numerosi servizi: analisi di laboratorio, diagnostica per immagini, cardiologia, dermatologia, oculistica, ortopedia, otorinolaringoiatria, broncopneumologia, allergologia, medicina del lavoro. A Solbiate lavora uno staff di 13 persone, sotto la guida del direttore sanitario Roberto Orsi.«Con grandissimo entusiasmo – dichiara il CEO di Cerba Healthcare Italia Stefano Massaro – diamo il benvenuto nel Gruppo Cerba al Centro Diagnostico Solbiatese, al dottor Roberto Orsi e a tutto il suo staff. L’operazione si inquadra nelle nostra strategia di acquisizioni di realtà d’eccellenza, con un grande radicamento nel territorio. Questo ci permette di crescere, affrontare le sfide del mercato sanitario e offrire servizi innovativi ai pazienti e ai professionisti del settore. A oggi serviamo 960.000 pazienti con 155 dipendenti e abbiamo 30 centri medici, una piattaforma di laboratorio HUB e 24 centri di prelievo».Cerba Healthcare Italia, che fa parte di un gruppo mondiale di 8.000 persone in grado di attrarre importanti investimenti internazionali, intende a crescere ancora nel nostro Paese con operazioni analoghe a quella appena conclusa a Solbiate Olona. «Anche questa acquisizione – prosegue Massaro – è il frutto del lavoro svolto con il nostro Jean Philippe Bezault, responsabile dello sviluppo M&A internazionale e il supporto di Adrien Sagnole e Bruno Borraccino. Al nostro fianco, come sempre, l’advisor Luca Marioli dello Studio Marioli Menotti e Associati e lo Studio Legale Orrick con il team degli avvocati Attilio Mazzilli, Livia Maria Pedroni e Angelo Timpanaro».
Con l’entrata in Cerba Healthcare, il CDS di Solbiate Olona potenzierà la propria capacità di offrire prestazioni di eccellenza con tariffe competitive, seguendo il paziente in modo personalizzato e in tutte le fasi della sua vita, con un accento particolare sulla prevenzione. Cerba HealthCare infatti è conosciuta per i suoi servizi innovativi, che integrando diverse discipline delineano percorsi su misura in diversi ambiti: è il caso del Medical Life Coaching, con viene individuato il corretto stile di vita sulla base delle caratteristiche di ciascuno, del Digital Life Coaching, volto a gestire gli effetti che la tecnologia ha sul benessere psico-fisico, e dei test genetici di ultima generazione proposti nell’ambito della medicina sportiva. Grazie a questo impegno Cerba HealthCare è stata inserita un uno studio (condotto da Industria Felix Magazine in collaborazione con l’ufficio studi di Cerved Group) su 140.000 aziende che colloca Cerba HC Italia al 38° posto fra i 771 “campioni” di resilienza che hanno affrontato e vinto la sfida della crisi: è l’unica azienda fra le prime 100 a occuparsi di servizi ambulatoriali ai pazienti e, per il settore sanitario in generale, è preceduta solo da due aziende farmaceutiche.

Posted in Economia/Economy/finance/business/technology | Contrassegnato da tag: , , | Leave a Comment »

12th Annual Healthcare CEOs Unscripted Conference

Posted by fidest press agency su sabato, 4 gennaio 2020

Bristol-Myers Squibb Company (NYSE: BMY) will take part in a fireside chat at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference on Thursday, January 9, 2020 in New York. Giovanni Caforio, M.D., chairman and chief executive officer will answer questions at 10:25 a.m. ET. Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. Materials related to the presentation will be available at the same website at the start of the live webcast. An archived edition of the session will be available later that day.
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

ViiV Healthcare receives complete response letter from US FDA

Posted by fidest press agency su martedì, 24 dicembre 2019

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, received a complete response letter (CRL) from the US Food and Drug Administration (FDA) regarding its application for cabotegravir and rilpivirine long-acting regimen for treatment of HIV-1 infection in virologically suppressed adults.The reasons given in the CRL relate to Chemistry Manufacturing and Controls (CMC). There have been no reported safety issues related to CMC and there is no change to the safety profile of the products used in clinical trials to date. ViiV Healthcare will work closely with the FDA to determine the appropriate next steps for this New Drug Application. Cabotegravir is an integrase strand transfer inhibitor developed by ViiV Healthcare and rilpivirine is a non-nucleoside reverse transcriptase inhibitor developed by Janssen Sciences Ireland UC. The cabotegravir and rilpivirine long-acting regimen is an investigational product and not approved anywhere in the world.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

38th Annual J.P. Morgan Healthcare Conference

Posted by fidest press agency su domenica, 22 dicembre 2019

Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the 38th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco on Wednesday, January 15, 2020, at 11:00 a.m. Pacific time (2:00 p.m. Eastern time).
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With approximately 19,000 Team Schein Members worldwide, the Company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Latin America Healthcare Leadership Briefing Forecast for 2020

Posted by fidest press agency su martedì, 10 dicembre 2019

The “Latin America Healthcare Leadership Briefing” country profile has been added to ResearchAndMarkets.com’s offering.Healthcare multinationals operating in Latin America continue to face rapidly evolving market-access conditions, especially in the region’s second-largest market, Mexico. The challenges faced in areas such as procurement, reimbursement, and product registration will not dissipate in the near term despite forecasted acceleration in healthcare spending in the region in 2020. To outperform market growth, regional and local teams will need to anticipate changes to healthcare policy as well as other conditions in the operating environment to design strategic initiatives within and across countries to capture upside opportunity. This report provides our views regarding healthcare expenditure growth across the region, key risks and opportunities that regional teams should be focused on, and actionable insights regarding the key strategic imperatives facing multinational healthcare companies in the Latin America region.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

38th Annual J.P. Morgan Healthcare Conference

Posted by fidest press agency su domenica, 8 dicembre 2019

Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco. José (Joe) E. Almeida, Baxter’s chairman and chief executive officer, is scheduled to present on Monday, January 13, 2020 at 10:00 a.m. Pacific Time.The live webcast of Baxter’s presentation, along with accompanying slides, can be accessed at http://www.baxter.com and will be available for replay through July 11, 2020. Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit http://www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Children’s Healthcare of Atlanta Christmas Parade

Posted by fidest press agency su venerdì, 6 dicembre 2019

The Aliera Companies, a holding and management company that provides compliance, accounting, human resources, and training services for its subsidiaries, today announced it is sponsoring the 39th annual Children’s Healthcare of Atlanta Christmas Parade.
Featuring an in-person visit from Santa Claus, dozens of floats, giant helium-filled balloons, marching bands and many other crowd favorites, the Children’s Christmas Parade is the largest holiday procession of its kind in the Southeast. With more than 3,000 participants, tens of thousands of spectators lining Atlanta’s famed Peachtree Street and hundreds of thousands more watching on WSB-TV, the festivities get underway Saturday Dec. 7, 2019 at 10:20 a.m. The parade will begin at the intersection of Peachtree and 16th streets and continue south on Peachtree for approximately one mile, concluding at Fifth Street.“I can think of no more appropriate way to commemorate this holiday season than by supporting one of the nation’s premier pediatric health care providers,” said Chase Moses, president of The Aliera Companies. “Many individuals in our extended family of companies have benefitted immensely from the skilled and compassionate care provided by the physicians and staff at Children’s Healthcare of Atlanta and we are proud to honor their work.” Dating to 1981, the parade is Children’s longest continuously running fundraiser and is the culmination of a year-round planning and coordination effort among staff and more than 500 volunteers. For those that cannot make it to Peachtree Street or tune in live, WSB-TV will re-air the parade on Christmas morning.The Children’s sponsorship is one of several charitable endeavors to which The Aliera Companies and its employees have committed this year. Others include the Atlanta Community Food Bank’s holiday food drive, One Warm Coat’s national clothing initiative and the Juvenile Diabetes Foundation’s One Walk Atlanta fundraiser.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

GlycoMimetics to Present at the Piper Jaffrey 31st Annual Healthcare Conference 2019

Posted by fidest press agency su martedì, 3 dicembre 2019

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the Piper Jaffrey 31st Annual Healthcare Conference in New York, New York, which takes place on December 3, 2019. Ms. King’s presentation is scheduled for 1:30 p.m. ET.To access the live webcast and subsequent archived recordings for this presentation, please visit the GlycoMimetics website at http://www.glycomimetics.com.
GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics’ wholly-owned drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including a Company-sponsored Phase 3 trial in relapsed/refractory AML. GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at http://www.glycomimetics.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

31st Annual Healthcare Conference

Posted by fidest press agency su domenica, 1 dicembre 2019

Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that Tim Moran, Chief Executive Officer, will present a company overview and update at the Piper Jaffray 31st Annual Healthcare Conference on Thursday, December 5th, at 1:00 p.m. ET in New York.A live audio webcast of the presentation will be accessible on the Events page of the Investors section on the Company’s website at http://www.motusgi.com. The webcast replay will be available approximately two hours after the presentation ends and will be accessible for 90 days.Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions. The Company’s flagship product is the Pure-Vu® System, a U.S. FDA cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard and slim colonoscopes to enable safe and rapid cleansing during the procedure while preserving established procedural workflow and techniques. Challenges with bowel preparation for inpatient colonoscopy represent a significant area of unmet need that directly affects clinical outcomes and increases the cost of care in a market segment that comprises approximately 1.5 million annual procedures in the U.S. and approximately 4 million annual procedures worldwide. Motus GI believes the Pure-Vu® System may improve outcomes and lower costs for hospitals by reducing the time to successful colonoscopy, minimizing delayed and incomplete procedures, and improving the quality of an exam. In clinical studies to date, the Pure-Vu® System significantly increased the number of patients with an adequate cleansing level, according to the Boston Bowel Preparation Scale Score, a validated assessment instrument.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

31st Annual Healthcare Conference

Posted by fidest press agency su venerdì, 29 novembre 2019

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Richard Rubino, Chief Financial Officer, will present in a fireside discussion at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 at 8:00 a.m. Eastern Time in New York, NY. Mr. Rubino will provide an Aerie overview and provide a business update. The fireside discussion will be webcast live and may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com. A replay of the webcast will be available for 10 business days.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

31st Annual Piper Jaffray Healthcare Conference

Posted by fidest press agency su giovedì, 28 novembre 2019

Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq: APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that company management will present at the 31st Annual Piper Jaffray Healthcare Conference at the Lotte New York Palace in New York, NY on December 5, 2019. The presentation is scheduled for 1:00 pm Eastern Time.
Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal defect repairs to the interventional treatment of obesity. Apollo’s device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo’s products are offered in over 80 countries today and include the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon. Apollo’s common stock is traded on Nasdaq Global Market under the symbol “APEN”. For more information regarding Apollo Endosurgery, go to: http://www.apolloendo.com.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Healthcare Robotics Engineering Forum

Posted by fidest press agency su martedì, 26 novembre 2019

Business-to-business publisher WTWH Media today announced that Ken Goldberg, William S. Floyd Distinguished Chair of Engineering, University of California, Berkeley, will deliver a keynote address at the 2019 Healthcare Robotics Engineering Forum. The Healthcare Robotics Engineering Forum, which takes place December 9-10, 2019 at the Santa Clara Convention Center, Santa Clara, CA, is a conference and expo focused on easing, speeding and improving the design, development and manufacture of healthcare robotics products and services. Ken Goldberg said, “Healthcare robotics is at an inflection point and attracting interest from leading corporations. Emerging advances in AI and Deep Learning have great potential to improve performance and clinical outcomes. I look forward to sharing new results from my lab and learning about exciting work on the next generation of these systems.”
The Healthcare Robotics Engineering Forum keynotes and general sessions are specifically designed to impart to technical professionals the information they need to successfully develop and manufacture healthcare robotics systems, while the exposition floor will provide attendees with direct access to the latest design and development solutions for producing healthcare robotics technologies and products. Tracks include Enabling Technologies, Tools and Platforms, Design and Development and Management and Opportunity. More information at http://www.healthcareroboticsforum.com.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Oncternal Therapeutics to Present at Piper Jaffray Healthcare Conference

Posted by fidest press agency su domenica, 24 novembre 2019

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the Piper Jaffray 31st Annual Healthcare Conference in New York City on Thursday, December 5, 2019 at 11:50 a.m. ET / 8:50 a.m. PT.A live webcast of the presentation will be available online via a link from the investor relations page of the Company’s website at http://www.oncternal.com, and the webcast will be archived there for at least 30 days following the event.
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The pipeline includes cirmtuzumab, an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), and TK216, an investigational targeted small-molecule inhibitor of the E26 transformation specific (ETS) family of oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. In addition, Oncternal has a program to develop a CAR-T therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. More information is available at http://www.oncternal.com.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

31st Annual Healthcare Conference

Posted by fidest press agency su sabato, 23 novembre 2019

Progenity, Inc. announced today that the company will be participating in the Piper Jaffray 31st Annual Healthcare Conference in New York, December 3-5. Progenity’s chief executive officer, Harry Stylli, PhD, will present a corporate overview on Wednesday, December 4, from 1:10 PM to 1:30 PM ET. Dr. Stylli and Eric d’Esparbes, chief financial officer, will also participate in one-on-one meetings with investors.
Progenity, Inc., is a privately held, biotechnology company with the mission of transforming healthcare to be more precise and personal. The company is translating innovation into precision medicine through diagnostic and therapeutic development platforms based on genomics/epigenomics, proteomics, and microbiomics. These platforms feed an R&D pipeline of innovative products designed to improve patient outcomes in prenatal and perinatal healthcare settings, oncology, and gastroenterology. Progenity’s ultimate vision is to make precision medicine a reality by both diagnosing disease at its source and treating it with targeted therapies developed by the company. Progenity is headquartered in San Diego, California. For more information on how Progenity is helping clinicians and patients prepare for life, please visit

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Stifel 2019 Healthcare Conference

Posted by fidest press agency su lunedì, 18 novembre 2019

Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced that Wendye Robbins, M.D., President and Chief Executive Officer, will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 1:50 p.m. Eastern Time.Blade Therapeutics is a private, clinical-stage biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs. Blade’s lead compound, BLD-2660, is a highly selective calpain inhibitor targeted for the treatment of chronic fibrotic diseases. BLD-2660 recently completed a Phase I, healthy volunteer, dose escalation study in Australia. The Company plans to submit a CTN application to initiate a Phase II trial in patients with idiopathic pulmonary fibrosis in early 2020. Blade’s second candidate, BLD-0409, is a Phase I ready autotaxin inhibitor for the treatment of multiple fibrotic diseases. The Company plans to initiate a Phase 1 study for BLD-0409 in 1Q 2020. Blade has assembled a critical mass of anti-fibrotic drug development expertise within its top-tier leadership team and a world-class network of advisors. Lead investors in Blade include MPM Capital, Deerfield, Pfizer Ventures, One Ventures, Osage Partners, Bristol-Myers Squibb and Novartis Institute of Biomedical Research. Please visit http://www.blademed.com/ for more information.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Savara to Present at the Stifel 2019 Healthcare Conference

Posted by fidest press agency su sabato, 16 novembre 2019

Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, will be presenting at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 3:00 PM ET / 12:00 PM PT at the Lotte New York Palace Hotel. Rob Neville, Savara’s Chief Executive Officer, will represent the Company at the conference. Interested parties can access a live audio webcast on the Investors page of the Savara website at http://www.savarapharma.com/investors/events-presentations/. Archived presentations will be available on Savara’s website for 90 days following the events.Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), in Phase 2a development for nontuberculous mycobacterial (NTM) lung infection in both non-cystic fibrosis (CF) and CF-affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3-stage inhaled vancomycin for treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

31st Annual Healthcare Conference

Posted by fidest press agency su venerdì, 15 novembre 2019

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming Piper Jaffray 31st Annual Healthcare Conference in New York City. AtriCure’s management is scheduled to present on Thursday, December 5, 2019, at 12:30 p.m. Eastern Time. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://ir.atricure.com.
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

The Jefferies London Healthcare Conference

Posted by fidest press agency su giovedì, 14 novembre 2019

London. CONMED Corporation (NASDAQ: CNMD) today announced that Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the Jefferies London Healthcare Conference at 9:20 a.m. GMT (4:20 a.m. ET) on Wednesday, November 20, 2019 in London, UK.A live webcast of the presentation will be accessible through the “Investors” section of the Company’s website at http://www.conmed.com and will be available for replay following the event. CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery, thoracic surgery and gastroenterology. For more information, visit http://www.conmed.com.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Oncternal Therapeutics to Present at Stifel Healthcare Conference

Posted by fidest press agency su giovedì, 14 novembre 2019

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19, 2019 at 10:20 a.m. ET / 7:20 a.m. PT.A live webcast of the presentation will be available online via a link from the investor relations page of the Company’s website at http://www.oncternal.com, and the webcast will be archived there for at least 30 days following the event.
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The pipeline includes cirmtuzumab, an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), and TK216, an investigational small-molecule compound that is designed to inhibit E26 transformation specific (ETS) family oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. In addition, Oncternal has a program to develop a CAR-T therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. More information is available at http://www.oncternal.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »